oligonucleotid
on
new
class
therapeut
compound
investig
treatment
varieti
diseas
state
cancer
hiv
fda
approv
anticmv
retin
antisens
molecul
vitraven
tm
isi
pharmaceut
howev
molecul
limit
poor
cellular
uptak
also
gener
lack
understand
regard
mechan
cellular
uptak
result
variou
deliveri
vehicl
develop
circumv
propos
mechan
uptak
endocytosi
improv
target
specif
deliveri
andor
drug
stabil
review
describ
variou
tradit
novel
deliveri
mechan
employ
improv
cellular
deliveri
cost
effect
therapeut
efficaci
approv
antisens
oligonucleotid
treatment
hivassoci
cmv
retin
vitraven
tm
isi
pharmaceut
signal
birth
new
class
therapeut
use
compound
sinc
conceptu
origin
on
investig
novel
therapeut
agent
current
investig
treatment
wide
varieti
diseas
cancer
viral
diseas
human
immunodefici
viru
hiv
hepat
cytomegaloviru
cmv
on
short
sequenc
singl
strand
nucleic
acid
nucleic
acid
analog
design
bind
intracellularli
target
nucleic
acid
rna
dna
protein
sequenc
conformationspecif
manner
addit
on
contain
specif
cpg
motif
elicit
immun
respons
although
clinic
relev
on
demonstr
poor
stabil
ineffici
cellular
uptak
vitro
vivo
limit
efficaci
on
barrier
therapeut
develop
cellular
uptak
dose
depend
chemistri
cell
type
wherea
intracellular
barrier
hinder
transport
intern
activ
site
result
concentr
activ
site
especi
term
vivo
drug
deliveri
may
low
effect
sustain
outcom
least
effici
deliveri
rather
poor
term
costeffect
drug
develop
inde
major
current
past
research
focus
improv
stabil
deliveri
modif
structur
via
use
deliveri
vehicl
protect
drug
degrad
well
improv
deliveri
cell
purpos
commun
review
mechan
cellular
uptak
well
common
novel
cellular
deliveri
method
advanc
drug
deliveri
varieti
mechan
develop
need
circumv
poor
cellular
uptak
nake
on
howev
basic
understand
propos
potenti
actual
mechan
uptak
would
use
deliveri
nake
on
also
develop
optim
deliveri
system
wide
accept
mechan
uptak
adsorpt
endocytosi
wherebi
adsorpt
cell
membran
result
transport
cell
via
endocytosi
howev
intracellular
local
vari
depend
cell
type
experiment
method
uptak
studi
signific
proport
intern
remain
sole
sequest
within
endosom
compart
evidenc
punctat
distribut
fluoresc
label
cell
unabl
escap
endosom
lysosom
degrad
like
howev
research
suggest
escap
endosom
either
rapidli
transport
nucleu
accumul
perinuclear
organel
current
mechan
on
escap
lysosom
degrad
transport
cytosol
nucleu
remain
unclear
mechan
cellular
uptak
propos
pinocytosi
caveolar
potocytosi
multitud
propos
mechan
indic
uptak
easili
defin
inde
mechan
vari
depend
chemic
structur
number
modif
nativ
phosphodiest
po
dna
backbon
synthes
improv
target
affin
intracellular
deliveri
stabil
on
presenc
abund
exoand
endonucleas
current
commonli
investig
on
phosphorothio
ps
methylphosphon
mp
chimer
backbon
contain
mix
backbon
chemistri
peptid
nucleic
acid
pna
figur
although
ps
modif
retain
aqueou
solubl
nativ
po
backbon
increas
stabil
presenc
nucleas
anion
charg
hinder
uptak
lipophil
membran
result
poor
cellular
uptak
tabl
howev
on
anion
backbon
like
po
ps
modif
bind
cell
surfac
protein
result
adsorpt
endocytosi
contrast
anion
on
neutral
molecul
like
mp
pna
surprisingli
low
cellular
uptak
result
low
cell
surfac
protein
bind
therefor
exhibit
decreas
adsorpt
endocytosi
cellular
uptak
also
highli
variabl
depend
cell
type
cell
cycl
exampl
cellular
uptak
cmyc
rauscher
erythroleukemia
cell
occur
via
nonspecif
protein
energydepend
pathway
immun
endocyt
inhibit
inconsist
endocytosi
alon
cellular
uptak
involv
signific
surfac
bind
well
cation
cell
cycl
depend
thu
multipl
mechan
uptak
rauscher
cell
line
may
occur
yet
complet
character
current
evid
may
also
suggest
porinlik
transport
pore
may
involv
cellular
uptak
final
research
demonstr
nuclear
perinuclear
fluoresc
without
punctat
fluoresc
pattern
suggest
either
nonendocyt
uptak
mechan
rapid
endosom
escap
therefor
altern
nonendocyt
multipl
mechan
cellular
uptak
plausibl
despit
unknown
mechan
uptak
on
hydrophil
macromolecul
intracellular
transport
activ
nake
on
observ
although
uptak
quit
ineffici
inde
sever
barrier
cellular
uptak
exist
must
overcom
improv
cellular
deliveri
first
barrier
lipophil
cell
membran
larg
anion
molecul
must
pass
reach
site
action
addit
mani
on
appear
enter
cell
endocytosi
alreadi
mention
result
sequestr
molecul
insid
endosom
must
pass
endosom
membran
risk
lysosom
degrad
final
although
evid
exist
insid
cytosol
on
rapidli
transport
nucleu
nucleas
within
intracellular
milieu
degrad
render
inact
ideal
optim
deliveri
on
site
action
would
base
thorough
understand
mechan
uptak
howev
mechan
transport
cell
remain
fulli
elucid
mani
research
focus
empir
develop
variou
novel
deliveri
vehicl
circumv
barrier
uptak
improv
efficaci
ultim
activ
on
wide
use
method
improv
stabil
intracellular
deliveri
util
onlipid
conjug
liposom
formul
liposom
compos
artifici
cation
lipid
n
propyl
n
n
ntrimethylammonium
chlorid
dotma
n
propyl
n
n
ntrimethylammonium
methyl
sulfat
dotap
cation
head
group
associ
neg
charg
on
neutral
anion
charg
facilit
deliveri
larg
anion
molecul
lipophil
cell
membran
uptak
occur
via
endocytosi
cation
liposom
induc
membran
flipflop
releas
liposom
cytosol
addit
addit
dioleyl
phosphatidylethanolamin
dope
liposom
formul
aid
destabil
endosom
membran
facilit
releas
site
action
encapsul
on
within
liposom
also
afford
protect
abund
nucleas
degrad
intracellular
milieu
howev
cation
liposom
cytotox
especi
high
concentr
limit
use
vitro
vivo
combat
drawback
associ
cation
liposom
modif
basic
liposom
formul
chang
lipid
composit
lipid
lipid
concentr
extens
investig
exampl
novel
nontox
liposom
formul
use
deliv
phosphorothio
antisens
neuropeptid
corticotropinreleas
factor
receptor
crfr
mrna
cho
cell
use
amphiphil
pyridiniumbas
lipid
onlipid
complex
form
use
mm
dope
nm
ps
po
anticrfr
increas
cellassoci
observ
follow
incub
complex
cho
cell
compar
free
addit
vitro
antisens
activ
result
decreas
crfr
mrna
express
use
complex
wherea
effect
observ
free
lipid
control
altern
phsensit
fusogen
liposom
use
bypass
endosoma
sequestr
phsensit
liposom
compos
amphipath
lipid
choleseryl
hemisuccin
chem
dope
physiolog
ph
chem
stabil
dope
lamellar
phase
liposom
howev
acid
ph
earli
endosom
chem
undergo
proton
result
format
hexagon
h
ii
phase
subsequ
fusion
destabil
endosom
membran
releas
cytosol
alter
lipid
composit
phsensit
liposom
increas
stabil
physiolog
ph
would
improv
circul
time
vivo
addit
phsensit
liposom
also
fusogen
properti
low
ph
result
releas
endosom
cytosol
phsensit
liposom
use
deliv
antisens
na
myoinositol
cotransport
mrna
astrocyt
cellular
uptak
effici
phsensit
liposom
use
compar
free
nonphsensit
liposom
lecithin
determin
use
fluoresc
microscopi
addit
phsensit
liposom
deliveri
result
decreas
target
mrna
express
compar
free
suggest
liposom
encapsul
signific
impact
deliveri
site
action
howev
evid
suggest
small
nm
phsensit
liposom
compos
dopeoa
stabil
presenc
human
plasma
via
insert
hydrophob
plasma
molecul
liposom
consequ
liposom
lose
ph
sensit
therefor
may
decreas
drug
deliveri
capabl
vivo
therefor
size
lipid
composit
interact
plasma
phsensit
liposom
need
care
character
adjust
achiev
optim
drug
deliveri
liposom
modifi
target
deliveri
coupl
receptor
ligand
antibodi
immunoliposom
liposom
exampl
maleylatedonbsa
conjug
effect
deliv
leishmaniainfect
macrophag
via
scaveng
receptor
system
result
nearli
decreas
parasiteinfect
macrophag
compar
result
free
pagnan
et
al
encapsul
cmyb
antisens
cation
liposom
coat
neutral
lipid
coval
coupl
antigangliosid
gd
monoclon
antibodi
gd
ccl
cellular
uptak
gd
posit
neuroblastoma
cell
significantli
higher
immunoliposomeencapsul
compar
free
result
signific
targetspecif
decreas
cmyb
express
addit
immunoliposomedirect
uptak
specif
gd
receptor
increas
uptak
compar
free
observ
hela
cell
gd
neg
cell
line
nonspecif
immunoliposom
use
result
suggest
nontarget
gd
neg
cell
may
larg
unaffect
gd
ccl
deliveri
system
use
vivo
antisens
treatment
neuroblastoma
receptormedi
endocytosi
rme
rmedirect
uptak
util
import
mechan
alreadi
present
cell
membran
uptak
biomolecul
necessari
cell
function
on
link
directli
carrier
protein
via
coval
bond
noncoval
via
polyllysin
pll
carrier
conjug
choic
carrier
depend
known
abil
bind
specif
cell
membran
receptor
accumul
cell
via
endocytosi
intern
potenti
improv
cellspecif
deliveri
also
achiev
target
receptor
sole
express
overexpress
certain
target
cell
exampl
although
folat
receptor
found
divid
cell
overexpress
epitheli
cancer
cell
therefor
investig
cellspecif
target
drug
ginobbi
cowork
use
folic
acidpllon
conjug
target
antisens
phosphorothio
cmyc
human
melanoma
cell
increas
intracellular
deliveri
observ
result
signific
decreas
cmyc
protein
level
cell
growth
control
investig
use
transferrinpllon
conjug
rme
observ
due
lack
transferrin
receptor
cell
inde
improv
uptak
activ
observ
suggest
target
specif
receptor
viabl
mean
limit
drug
deliveri
specif
cell
popul
howev
effect
drugtarget
rme
depend
affin
ligand
receptor
also
limit
select
receptor
target
cell
especi
vivo
addit
ligand
must
either
inact
augment
therapeut
outcom
avoid
potenti
toxic
associ
deliveri
vehicl
therefor
thorough
character
select
receptor
vivo
ubiqu
lack
thereof
prerequisit
develop
rme
deliveri
hepatocytespecif
drug
deliveri
treatment
hepat
diseas
investig
target
asialoglycoprotein
receptor
biessen
cowork
deliv
random
sequenc
parenchym
liver
cell
derivat
l
g
lysinebas
galactosid
synthet
ligand
high
affin
asialoglycoprotein
receptor
although
conjug
l
g
slightli
decreas
affin
l
g
asor
receptor
k
versu
nm
bind
target
sequenc
vitro
assay
significantli
affect
presenc
l
g
suggest
vitro
activ
would
affect
ligand
author
also
suggest
uptak
occur
via
activ
transport
intracellular
concentr
nm
higher
extracellular
concentr
wherea
cellular
uptak
decreas
least
addit
variou
uptak
inhibitor
addit
uptak
onl
g
conjug
significantli
decreas
almost
presenc
competit
asor
receptor
ligand
galnac
asor
howev
confoc
analysi
onligand
uptak
use
rhodaminelabel
show
mainli
punctat
fluoresc
pattern
minor
amount
fluoresc
cytosol
suggest
sequest
within
endosom
compart
vivo
intraven
administr
ponl
g
conjug
mice
demonstr
signific
alter
distribut
plasma
clearanc
rapid
min
inject
free
conjug
respect
remain
plasma
howev
wherea
free
found
liver
l
g
conjug
increas
deliveri
liver
conjug
increas
select
deliveri
liver
also
conjug
success
bypass
reticuloendotheli
clearanc
scavengerreceptor
uptak
within
liver
increas
conjug
deliveri
parenchym
liver
rather
kupffer
endotheli
liver
cell
observ
compar
free
hepat
distribut
therefor
conjug
may
potenti
employ
select
deliv
on
use
rme
vitro
vivo
howev
studi
regard
vitro
vivo
activ
conjug
necessari
determin
overal
efficaci
asor
rme
deliveri
on
liver
mani
cellspecif
receptor
may
prove
use
target
deliveri
enhanc
deliveri
investig
use
mannos
deliveri
alveolar
macrophag
human
tumor
target
use
transferrin
antitransferrin
antibodi
antitransferrin
antibodyon
conjug
also
use
target
deliveri
brain
conjug
use
target
monocyt
epiderm
growth
factor
egf
receptor
target
deliveri
egfon
conjug
epitheli
cancer
cell
howev
rme
gener
result
sequestr
endosom
compart
therebi
limit
util
method
deliv
therapeut
level
drug
intracellular
target
addit
onprotein
conjug
must
care
design
hinder
receptorligand
bind
block
receptorbind
site
carrier
protein
fusogen
peptid
use
promot
peptid
fusion
onpeptid
conjug
either
cell
lysosom
membran
exampl
morri
et
al
develop
peptid
vector
contain
hydrophob
hiv
fusion
peptid
hydrophil
tantigen
creat
onpeptid
conjug
via
electrostat
interact
hydrophil
peptid
use
confoc
microscopi
cellular
uptak
conjug
observ
occur
via
nonendocyt
pathway
on
local
nucleu
within
h
cell
wherea
littl
punctat
fluoresc
observ
contrast
follow
endocytosi
conjug
influenza
viru
hemagglutinin
ha
envelop
fusion
peptid
acidif
endosom
compart
result
conform
chang
ha
destabil
lysosom
membran
releas
conjug
cytosol
freulon
cowork
investig
uptak
antisens
gem
hela
cell
coincub
unconjug
either
monomer
dimer
ctermin
subunit
hela
cell
slightli
acid
media
acid
condit
peptid
destabil
endosom
membran
allow
deliveri
cytosol
complet
uptak
mm
fluoresc
label
occur
use
mm
monom
ph
follow
incub
uptak
similar
use
differ
fluorophor
cell
line
backbon
depend
ph
support
role
endosom
acidif
ha
fusion
peptidemedi
deliveri
confoc
analysi
indic
peptid
coloc
endosom
compart
prior
acidif
howev
follow
acidif
endosom
membran
destabil
on
local
nucleu
wherea
remain
cytosol
although
vitro
activ
studi
done
potenti
increas
activ
lower
concentr
suggest
remain
free
uncomplex
peptid
vector
deliveri
nucleu
improv
compar
alon
select
import
nuclear
protein
cytosol
nucleu
mediat
short
peptid
sequenc
call
nuclear
local
signal
nl
nl
peptid
deriv
transcript
nuclear
factor
kb
influenza
viral
nucleoprotein
yeast
protein
use
facilit
transport
nucleu
addit
nl
signal
import
peptid
ip
promot
cellular
uptak
ip
dna
deriv
kaposi
fibroblast
growth
factor
kfgf
dna
uptak
stimul
factor
dusf
neurospora
crassa
respect
synthet
ip
kfgf
promot
transient
pore
format
cell
membran
cell
uptak
onpllip
conjug
dose
depend
mm
ippl
result
strong
intracellular
cytoplasm
nuclear
fluoresc
via
nonendocyt
pathway
demonstr
confoc
microscopi
endocytosi
inhibit
studi
competit
studi
also
indic
uptak
mechan
receptor
mediat
howev
similar
studi
use
onkfgf
disulfid
conjug
monkey
kidney
fibroblast
cho
human
retin
pigment
epitheli
cell
result
punctat
distribut
faint
nuclear
cytosol
fluoresc
suggest
mechan
kfgfmediat
deliveri
vari
among
cell
line
method
onpeptid
conjug
strongli
affect
deliveri
mechan
final
multipl
import
mechan
may
combin
optim
deliveri
peptid
deriv
hiv
tat
drosophila
antennapedia
protein
serv
cell
membran
transloc
signal
well
nuclear
transport
signal
fusion
peptidenl
conjug
often
use
deliv
on
includ
deliveri
assemblag
like
kfgfnl
protaminenl
cyclodextrin
cd
cyclic
oligosaccharid
consist
hydrophob
central
caviti
multipl
hydroxyl
group
outer
surfac
figur
uniqu
abil
associ
molecul
water
solubl
potenti
derivat
hydroxyl
group
central
caviti
cd
investig
deliveri
varieti
drug
molecul
cd
deliveri
system
also
use
minim
drug
toxic
enhanc
bioavail
via
multipl
deliveri
rout
bcd
use
deliv
phosphorothio
varieti
human
tcell
leukemia
cell
line
author
report
cellular
uptak
improv
presenc
cd
h
uptak
depend
concentr
cd
importantli
on
remain
activ
cd
deliveri
use
antivir
activ
antisens
target
coronaviru
adenocarcinoma
cell
increas
almost
mm
deliv
use
cd
deriv
compar
free
viral
inhibit
cell
toxic
associ
cd
cd
also
use
deliv
on
vivo
zhao
cowork
use
cd
deliv
on
contain
immunogen
cpg
sequenc
mice
dose
mgkg
vari
concentr
cd
author
found
cdmediat
deliveri
result
decreas
mitogen
lack
splenomegali
increas
igm
product
compar
free
howev
coadminist
protect
effect
cd
onassoci
toxic
decreas
time
clearanc
cd
much
rapid
although
mechan
cd
inhibit
immun
stimul
on
unclear
author
suggest
possibl
inclus
within
cd
caviti
block
potenti
onprotein
bind
protein
involv
lymphocyt
activ
therefor
cdon
formul
must
optim
retain
improv
deliveri
stabil
on
lengthen
time
frame
cd
also
protect
similarli
barrett
et
al
found
cellular
uptak
bcdadamantylon
conjug
cell
enhanc
compar
free
addit
follow
system
administr
conjug
mice
uptak
dorsal
root
ganglia
liver
kidney
brain
increas
compar
free
suggest
cd
may
use
target
specif
diseas
site
vivo
dendrim
highli
branch
macromolecul
synthes
multipl
seri
repetit
unit
typic
polyamid
figur
molecul
surfac
function
group
primari
amino
group
interact
molecul
via
electrostat
interact
result
rapid
highli
reproduc
complex
format
occur
yield
complex
weak
cytotox
increas
research
investig
potenti
dendrim
andor
dna
deliveri
vehicl
recent
occur
bielinska
et
al
investig
cellular
uptak
vitro
activ
antiluciferas
either
free
complex
gener
starburst
pamam
polyamidoamin
dendrim
use
luciferas
express
jurkat
rat
cell
dendrimeron
complex
variou
charg
ratio
result
increas
cellular
uptak
decreas
luciferas
express
compar
free
cell
line
suggest
increas
cytosol
deliveri
addit
on
deliv
use
dendrim
significantli
higher
retent
cell
day
compar
h
free
similarli
yoo
juliano
investig
mechan
dendrimermedi
cellular
uptak
hela
cell
use
tamralabel
onoregon
green
gener
pamam
dendrim
dendrimeron
complex
remain
intact
intracellularli
although
presum
bound
plasma
membran
endosom
compart
also
coloc
cytoplasm
nucleu
much
higher
extent
free
similar
result
bielinska
et
al
data
suggest
dendrim
enhanc
extraendosom
deliveri
on
addit
deliveri
presenc
fc
possibl
use
dendrim
wherea
liposom
formul
lipofectamin
typic
inact
presenc
serum
therefor
lack
cytotox
enhanc
deliveri
on
even
presenc
serum
possibl
given
dendrim
advantag
tradit
deliveri
vehicl
like
liposom
cyanoacryl
nanoparticl
studi
drug
deliveri
tool
sinc
late
deliveri
tool
sinc
earli
drugnanoparticl
associ
achiev
hydrophob
van
der
waal
interact
anion
charg
necessit
format
ion
pair
use
variou
hydrophob
cation
prior
load
nanoparticl
typic
alkylcyanoacryl
polyisohexyl
pihca
polyisobutyl
pibca
polyhexycyanoacryl
phca
use
form
nanoparticl
although
varieti
lipophil
cationon
ion
pair
test
adsorpt
nanoparticul
system
depend
type
cyanoacryl
use
respect
hydrophob
also
length
type
hydrophob
cation
use
addit
adsorpt
nanoparticl
invers
relat
ionic
strength
formul
use
onctab
hexadecylmethylammonium
pihca
nanoparticl
helen
cowork
investig
cellular
uptak
stabil
on
cell
cellfre
system
nanoparticleencapsul
stabl
h
presenc
phosphodiesteras
wherea
free
degrad
within
min
similarli
serumcontain
cell
cultur
medium
nanoparticl
abl
protect
on
nucleas
degrad
h
wherea
rapidli
degrad
unencapsul
final
uptak
nanoparticl
higher
unencapsul
on
follow
incub
cell
observ
cytotox
littl
vivo
work
done
use
nanoparticl
deliveri
system
exampl
tumor
growth
nude
mice
inhibit
intratumor
inject
antihara
adsorb
pihca
nanoparticl
requir
significantli
less
inject
free
alon
similarli
lambert
et
al
found
ewe
sarcomarel
tumor
size
nude
mice
smaller
follow
intratumor
inject
antiew
adsorb
pica
nanoparticl
compar
free
follow
day
treatment
final
studi
use
pd
ctabpibca
nanoparticl
deliv
mice
indic
stabil
improv
compar
free
on
plasma
liver
addit
plasma
halflif
significantli
alter
distribut
on
encapsul
nanoparticl
shift
liver
organ
nanoparticl
encapsul
increas
vitro
vivo
cellular
uptak
on
littl
cytotox
increas
vitro
nucleas
stabil
although
cell
uptak
presum
activ
limit
endosom
sequestr
chemic
modif
nanoparticl
improv
cytosol
nuclear
deliveri
on
vivo
may
possibl
addit
nanoparticl
may
advantag
deliveri
system
target
deliveri
on
liver
recent
use
microparticul
deliveri
system
investig
sustainedreleas
deliveri
on
microparticl
microspher
microns
deliveri
system
typic
compos
biodegrad
polym
poli
llactidecoglycolid
p
laga
advantag
microspher
formul
slow
releas
encapsul
drug
exampl
de
rosa
et
al
investig
cellular
uptak
poli
dt
on
encapsul
mm
p
laga
micropher
hela
cell
releas
microspher
triphas
indic
initi
burst
phase
slowreleas
phase
occur
day
eventu
bulk
eros
microspher
addit
encapsul
effici
releas
rate
could
control
addit
polyethylenimin
pei
interestingli
confoc
microscopi
hela
cell
incub
onpei
microsphereencapsul
onpei
demonstr
increas
cytosol
nuclear
deliveri
rhodaminelabel
author
propos
extracellular
control
releas
micropher
prevent
satur
pinocytot
uptak
result
increas
cytoplasm
accumul
nuclear
deliveri
on
similar
result
demonstr
follow
encapsul
cmyc
tat
poon
mm
p
laga
microspher
author
found
releas
triphas
initi
burst
phase
first
h
microspher
degrad
day
microspher
incub
physiolog
buffer
addit
stabil
on
significantli
improv
presenc
serum
yet
onrna
hybrid
hinder
microspher
encapsul
therefor
develop
microspher
deliveri
system
on
may
improv
cellular
deliveri
on
minim
need
multipl
dose
on
addit
molecularand
chemicalbas
strategi
deliv
on
cell
physic
method
deliveri
also
report
deliveri
method
util
physic
forc
electr
pressur
sound
electropor
deliveri
techniqu
util
high
intens
electr
field
destabil
lipid
bilay
therebi
permeabil
cell
membran
allow
increas
transport
drug
ioniz
drug
iontophoresi
target
cell
electropor
success
use
enhanc
transderm
deliveri
on
deliv
ex
vivo
vivo
studi
zewert
cowork
success
increas
transderm
deliveri
cmyb
cmyc
antisenseon
heatstrip
stratum
corneum
use
electropor
increas
cmyband
cmycon
transport
respect
observ
puls
v
appli
everi
h
compar
prepuls
transport
transport
occur
result
electrophoresi
skin
rather
preexist
pore
hair
follicl
electropor
appli
success
vivo
deliveri
antisenseon
rat
applic
section
rat
liver
vivo
result
select
transfer
liposomeencapsul
liver
within
target
zone
yield
increas
apoptosi
precancer
cell
therefor
deliveri
anticanc
on
conjunct
surgic
remov
andor
exposur
cancer
tissu
may
prove
effect
combin
treatment
addit
vivo
experi
ex
vivo
treatment
bone
marrow
cmyc
antisenseon
electropor
investig
purg
bone
marrow
contamin
cancer
cell
autolog
transplant
studi
mice
shown
immedi
decreas
myc
protein
ontreat
sampl
rapid
select
cell
death
cancer
cell
littl
observ
effect
hematopoeit
reconstitut
combin
result
literatur
suggest
electropor
potenti
effect
method
deliveri
on
via
transderm
rout
may
facilit
select
deliveri
either
vivo
ex
vivo
applic
pressur
nake
deliveri
system
investig
vitro
ex
vivo
inhibit
bypass
graft
cardiac
allograft
reject
studi
rat
carotid
arteri
demonstr
pressuredepend
uptak
fitcon
use
infus
pressur
mmhg
neointim
medial
adventiti
cell
nuclei
respect
posit
fitcon
day
ex
vivo
experi
excis
rat
heart
submers
solut
follow
inject
solut
coronari
circul
atm
pressur
ambient
pressur
heart
transplant
harvest
day
postop
level
measur
maxim
uptak
effici
observ
appli
myocardi
surfac
well
circul
min
atm
alreadi
describ
wherea
uptak
occur
appli
ambient
pressur
neutrophil
infiltr
edema
histolog
chang
observ
microscopi
myocardi
cell
suggest
uptak
bypass
endosom
sequestr
result
direct
transport
nucleu
although
deliveri
cell
andor
tissu
improv
use
pressuremedi
deliveri
need
close
system
pressur
may
limit
techniqu
ex
vivo
procedur
use
shockwav
acoust
highenergi
pressur
puls
novel
method
cytoplasm
deliveri
recent
introduc
shock
wave
deliv
fluid
medium
focus
target
area
deliveri
sequenti
posit
neg
pressur
wave
caus
air
bubbl
secondari
shock
wave
emiss
result
transient
pore
format
cell
membran
cavit
lithotript
nf
hz
kv
use
deliv
shockwav
pbmc
hela
cell
presenc
mm
antitnfaon
follow
shockwav
cell
wash
place
bar
pressur
fitcon
uptak
measur
flow
cytometri
fluoresc
microscopi
tnfa
product
measur
elisa
cell
viabil
remain
cell
uptak
depend
number
shockwav
concentr
distribut
cell
initi
homogen
follow
accumul
nucleu
mm
use
shockwav
inhibit
tnfa
observ
compar
cell
treat
absenc
shockwav
compar
electropor
result
spotti
fluoresc
cell
membran
littl
nuclear
accumul
lower
vitro
activ
shockwav
therefor
may
advantag
deliveri
mechan
nonendosom
deliveri
level
adjust
alter
concentr
achiev
addit
deliveri
reproduc
appli
variou
cell
type
although
high
volum
solut
requir
techniqu
may
somewhat
limit
widespread
applic
improv
vivo
gene
transfer
mous
melanoma
cell
demonstr
administr
shockwav
follow
inject
air
tumor
volum
improv
acoust
cavit
therefor
shockwavemedi
deliveri
may
potenti
success
method
deliveri
ultrasound
ultrasound
acoust
techniqu
similar
shockwav
one
use
higher
frequenc
mhz
versu
hz
shorter
overal
applic
time
second
minut
recent
use
ultrasound
enhanc
dna
transfect
gene
therapi
investig
vitro
experi
ultrasound
wave
transmit
cell
cultur
flask
wall
permeabil
cell
membran
allow
dna
enter
cell
continu
wave
frequenc
primari
rat
fibroblast
chondrocyt
transient
transfect
lacz
neo
genecontain
plasmid
effici
addit
durat
mhz
ultrasound
treatment
littl
decreas
cell
viabil
observ
huber
et
al
compar
shockwav
ultrasound
transfect
bgal
luciferas
express
plasmid
hela
cell
luciferas
express
maxim
follow
hz
ultrasound
durat
min
mpa
pressur
treatment
result
transfect
viabl
cell
increas
transfect
absenc
ultrasound
comparison
although
shockwavemedi
transfect
increas
number
wave
deliv
increas
transfect
rate
observ
partial
due
reduct
cell
viabil
therefor
ultrasound
may
prove
effici
less
toxic
mean
shockwav
deliv
dna
cell
futur
studi
may
prove
ultrasound
also
use
effect
deliv
shorter
dna
strand
like
on
cell
tissu
whether
vitro
vivo
vitro
uptak
nake
on
cell
highli
ineffici
necessit
novel
deliveri
method
addit
endosom
sequestr
commonli
observ
limit
concentr
target
site
cytosol
andor
nucleu
review
describ
variou
standard
novel
techniqu
current
use
enhanc
deliveri
cell
cultur
sever
techniqu
electropor
liposom
nanoparticl
pressur
dendrim
also
investig
vivo
potenti
deliveri
system
therapeut
applic
on
addit
deliveri
method
bypass
destabil
endosom
may
prove
use
endosom
escap
major
limit
factor
drug
accumul
target
site
signific
progress
made
area
drug
deliveri
although
question
remain
regard
toxic
stabil
optim
variou
deliveri
system
therapeut
use
system
may
prove
necessari
effect
use
on
clinic
set
